Zephyr Health announced it has raised a $15 million Series B funding round that was co-led by Kleiner Perkins Caufield & Byers and Jafco Ventures. The San Francisco-based company, which provides companies in the life sciences industry a big data analytics platform, previously raised $1 million in funding from a private individual investor. As part of the recent round, Brook Byers, general partner at Kleiner Perkins, and Joe Horowitz, managing general partner at Jafco, have joined the board.
CORRECTION: An earlier version of the summary above misidentified the $15 million funding round. It was a Series B round.
Zephyr Health Raises $15 Million; Offers Big Data Analytics Platform for Life Sciences and Healthcare Industry
Kleiner Perkins Caufield & Byers and Jafco Ventures Co-Lead Series B; Brook Byers and Joe Horowitz Added to the Board
SAN FRANCISCO, CA – January 8, 2014 – Today, Zephyr Health, a fast-growing big data analytics platform for companies in the life sciences industry, announced a $15 million funding round co-led by Kleiner Perkins Caufield & Byers and Jafco Ventures. In addition to the company’s funding, Zephyr Health also announced the addition of Brook Byers, general partner at Kleiner Perkins Caufield & Byers (KPCB), and Joe Horowitz, managing general partner at Jafco Ventures, to its Board of Directors.
“A key problem today for life science companies of all sizes is the enormous scale and variety of data they must deal with in largely disconnected environments,” said William King, CEO and founder of Zephyr Health. “Zephyr’s platform leverages NoSQL data bases, machine-based algorithms, and exceptional visualization to put valuable insights directly into the hands of business leaders and decision-makers. We are delighted to have the support of KPCB and Jafco Ventures in pursuing our mission of transforming data in the life sciences industry.”
Zephyr’s platform is specially designed to help life sciences companies improve R&D efforts and bring new treatments to the right physicians in the treatment landscape. Through the platform, customers are able to greatly reduce the time and cost it takes to research and bring a therapy to market. Five of the world’s largest pharmaceutical and device companies are already working closely with Zephyr Health and seeing impactful results from the platform.
“Having worked with over 100 innovative pharmaceutical, biotechnology, and medical device companies for decades, Zephyr Health offers the most compelling business solutions that I have seen,” said Brook Byers, general partner at KPCB. “The insights they afford are nothing short of remarkable and can be of great benefit to everyone from the CEO on down throughout the organization. We look forward to leveraging our extensive industry network to help Zephyr accelerate customer adoption and realize its enormous value.”
“One of the many things that attracted us to Zephyr Health is the quality of their value proposition and their rate of customer traction,” said Joe Horowitz, managing general partner at Jafco Ventures. “Having worked with industry leaders in cloud computing and the big data spaces, Zephyr clearly stands out as a highly focused business poised for tremendous success.”
It can take up to ten years to get a drug to market at a cost of up to $4 billion. By breaking down the silos that divide data, Zephyr helps connect information that otherwise cannot be seen as a whole so that drug and life sciences companies can bring effective therapies to market faster and less expensively than ever before.
“The ability to intuitively derive value from the data through Zephyr’s suite of cloud applications has already changed the landscape of decision-making in life sciences,” said William King. “Now with this financing from two leading venture firms, we are off to the races to establish Zephyr Health as the leader in data management and analytics for this market.”
For more information, please visit www.zephyrhealthinc.com.
About Zephyr Health
Founded in 2011, Zephyr Health, Inc., is focused on bringing large amounts of disconnected data together seamlessly, with a highly differentiated data visualization ecosystem that enables life sciences professionals to analyze and gather insights from the information. A core value of the company is “simplicity on the edge of complexity.” The platform is deployed across a wide spectrum of business critical environments within the life sciences industry, including Clinical Operations, Medical Affairs, Sales & Marketing and Payers. For more information, please visit www.zephyrhealthinc.com.
About Kleiner Perkins Caufield & Byers (KPCB)
Kleiner Perkins Caufield & Byers (KPCB) has backed entrepreneurs in more than 700 ventures leading to nearly 200 IPOs, over 375,000 jobs and a very extensive strategic network. The firm has helped build pioneering companies like Align, Amazon, Electronic Arts, Foundation Medicine, Genentech, Genomic Health, Google, Intuit, Juniper Networks, Netscape, Symantec, Twitter, VeriSign and WebMD. KPCB partners serve on the boards of Amazon, Apple, Bloom Energy, Flipboard, Foundation Medicine, Google, Hewlett-Packard, Nest, Square, Tesaro and Zynga, among others. KPCB accelerates the success of entrepreneurs with a team of partners delivering company-building services including strategy, operational scaling, recruiting, business development, product delivery and marketing communications. The firm invests in all stages from seed and incubation to growth companies. KPCB operates from offices in Menlo Park, San Francisco, Shanghai and Beijing. http://www.kpcb.com
Based in Palo Alto, Jafco Ventures is a venture capital partnership that invests in early-stage companies with great teams that demonstrate differentiated technology, compelling business models and momentum in their respective markets. The firm’s focus is to help portfolio companies efficiently scale to realize great outcomes. Jafco Ventures has had the privilege to invest in market-leading companies such as Aster Data, FireEye, 41st Parameter, Infinera, MoPub, Palo Alto Networks, and Proofpoint. To support this challenge the partnership consists of a core team of proven, early-stage venture capital investors, augmented by venture partners with best-in-class experience in scaling companies and a world-class business development team based in Tokyo. For more information about Jafco Ventures visit www.jafco.com.